

Laura Poliseno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/745364/publications.pdf>

Version: 2024-02-01

58
papers

12,063
citations

304743

22
h-index

175258

52
g-index

62
all docs

62
docs citations

62
times ranked

16057
citing authors

#	ARTICLE	IF	CITATIONS
1	A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?. <i>Cell</i> , 2011, 146, 353-358.	28.9	5,954
2	A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. <i>Nature</i> , 2010, 465, 1033-1038.	27.8	2,133
3	Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs. <i>Cell</i> , 2011, 147, 344-357.	28.9	926
4	MicroRNAs modulate the angiogenic properties of HUVECs. <i>Blood</i> , 2006, 108, 3068-3071.	1.4	693
5	MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling. <i>Cell</i> , 2013, 154, 311-324.	28.9	417
6	Identification of the miR-106b ~ miR-25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation. <i>Science Signaling</i> , 2010, 3, ra29.	3.6	390
7	microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. <i>EMBO Journal</i> , 2011, 30, 1990-2007.	7.8	228
8	Pseudogenes: Newly Discovered Players in Human Cancer. <i>Science Signaling</i> , 2012, 5, re5.	3.6	125
9	PTEN ceRNA networks in human cancer. <i>Methods</i> , 2015, 77-78, 41-50.	3.8	121
10	Deletion of PTENP1 Pseudogene in Human Melanoma. <i>Journal of Investigative Dermatology</i> , 2011, 131, 2497-2500.	0.7	99
11	LRF Is an Essential Downstream Target of GATA1 in Erythroid Development and Regulates BIM-Dependent Apoptosis. <i>Developmental Cell</i> , 2009, 17, 527-540.	7.0	97
12	Pseudogenes in Human Cancer. <i>Frontiers in Medicine</i> , 2015, 2, 68.	2.6	92
13	Long non-coding RNAs in cancer: implications for personalized therapy. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 17-28.	4.4	92
14	The Proto-Oncogene LRF Is under Post-Transcriptional Control of MiR-20a: Implications for Senescence. <i>PLoS ONE</i> , 2008, 3, e2542.	2.5	79
15	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. <i>Oncotarget</i> , 2017, 8, 25395-25417.	1.8	64
16	The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma. <i>PLoS ONE</i> , 2011, 6, e25264.	2.5	60
17	Integrative Genomics Identifies Molecular Alterations that Challenge the Linear Model of Melanoma Progression. <i>Cancer Research</i> , 2011, 71, 2561-2571.	0.9	57
18	Biosafety and Biokinetics of Noble Metals: The Impact of Their Chemical Nature. <i>ACS Applied Bio Materials</i> , 2019, 2, 4464-4470.	4.6	49

#	ARTICLE	IF	CITATIONS
19	Histology-Specific MicroRNA Alterations in Melanoma. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1860-1868.	0.7	46
20	Hedgehog Pathway Blockade Inhibits Melanoma Cell Growth in Vitro and in Vivo. <i>Pharmaceuticals</i> , 2013, 6, 1429-1450.	3.8	40
21	miRNAs Regulate miRNAs: Coordinated Transcriptional and Post-Transcriptional Regulation. <i>Cell Cycle</i> , 2006, 5, 2473-2476.	2.6	33
22	Antitumoral effects of attenuated <i>Listeria monocytogenes</i> in a genetically engineered mouse model of melanoma. <i>Oncogene</i> , 2019, 38, 3756-3762.	5.9	30
23	Suppression of <i>CHK1</i> by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. <i>Cancer Discovery</i> , 2015, 5, 550-563.	9.4	24
24	The landscape of BRAF transcript and protein variants in human cancer. <i>Molecular Cancer</i> , 2017, 16, 85.	19.2	22
25	The Energy Profiling of Short Interfering RNAs Is Highly Predictive of Their Activity. <i>Oligonucleotides</i> , 2004, 14, 227-232.	2.7	16
26	Resting smooth muscle cells as a model for studying vascular cell activation. <i>Tissue and Cell</i> , 2006, 38, 111-120.	2.2	16
27	Biological role of miR-204 and miR-211 in melanoma. <i>Oncoscience</i> , 2018, 5, 248-251.	2.2	15
28	Bcl2-negative MCF7 cells overexpress p53: implications for the cell cycle and sensitivity to cytotoxic drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 127-130.	2.3	14
29	MICAL2 is expressed in cancer associated neo-angiogenic capillary endothelia and it is required for endothelial cell viability, motility and VEGF response. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2111-2124.	3.8	14
30	PTENP1 is a ceRNA for PTEN: it's CRISPR clear. <i>Journal of Hematology and Oncology</i> , 2020, 13, 73.	17.0	13
31	Identification of BRAF 3'UTR Isoforms in Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1694-1697.	0.7	12
32	Systematic evaluation of the microRNAome through miR-CATCHv2.0 identifies positive and negative regulators of <i>BRAF-X1</i> mRNA. <i>RNA Biology</i> , 2019, 16, 865-878.	3.1	10
33	Bcl2-low-expressing MCF7 cells undergo necrosis rather than apoptosis upon staurosporine treatment. <i>Biochemical Journal</i> , 2004, 379, 823-832.	3.7	9
34	Development of a yeast-based system to identify new hBRAFFV600E functional interactors. <i>Oncogene</i> , 2019, 38, 1355-1366.	5.9	8
35	A eutherian-specific microRNA controls the translation of <i>Satb2</i> in a model of cortical differentiation. <i>Stem Cell Reports</i> , 2021, 16, 1496-1509.	4.8	8
36	RNA-Based Drugs: From RNA Interference to Short Interfering RNAs. <i>Current Pharmaceutical Biotechnology</i> , 2004, 5, 361-368.	1.6	8

#	ARTICLE	IF	CITATIONS
37	Proteomics pipeline for phosphoenrichment and its application on a human melanoma cell model. <i>Talanta</i> , 2020, 220, 121381.	5.5	7
38	Pseudogenes. <i>Methods in Molecular Biology</i> , 2014, 1167, v.	0.9	5
39	Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. <i>Pharmacogenomics Journal</i> , 2019, 19, 455-464.	2.0	5
40	The Sensitivity of MCF10A Breast Epithelial Cells to Alkylating Drugs is Enhanced by the Inhibition of O6-Methylguanine-DNA Methyltransferase Transcription with a Synthetic Double Strand DNA Oligonucleotide. <i>Breast Cancer Research and Treatment</i> , 2002, 73, 207-213.	2.5	3
41	Pro64His (rs4644) Polymorphism Within Galectin-3 Is a Risk Factor of Differentiated Thyroid Carcinoma and Affects the Transcriptome of Thyrocytes Engineered via CRISPR/Cas9 System. <i>Thyroid</i> , 2021, 31, 1056-1066.	4.5	3
42	In Vivo Silencing/Overexpression of lncRNAs by CRISPR/Cas System. <i>Methods in Molecular Biology</i> , 2021, 2348, 205-220.	0.9	3
43	Methods for the Identification of PTEN-Targeting MicroRNAs. <i>Methods in Molecular Biology</i> , 2016, 1388, 111-138.	0.9	3
44	Inducible modulation of miR-204 levels in a zebrafish melanoma model. <i>Biology Open</i> , 2020, 9, .	1.2	3
45	Ensemble Modeling Approach Targeting Heterogeneous RNA-Seq data: Application to Melanoma Pseudogenes. <i>Scientific Reports</i> , 2017, 7, 17344.	3.3	2
46	Distinguishing between nodular and superficial spreading melanoma using specific microRNA alterations.. <i>Journal of Clinical Oncology</i> , 2011, 29, 8540-8540.	1.6	2
47	Identification of active siRNAs against IGF-IR of porcine coronary smooth muscle cells in a heterologous cell line. <i>International Journal of Molecular Medicine</i> , 2005, 15, 713.	4.0	1
48	Alkaline Phosphatase-Positive Immortal Mouse Embryo Fibroblasts Are Cells in a Transitional Reprogramming State Induced to Face Environmental Stresses. <i>Genetics & Epigenetics</i> , 2015, 7, GEG.S27696.	2.5	1
49	P-198 Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib. <i>Annals of Oncology</i> , 2015, 26, iv57.	1.2	1
50	Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	1
51	Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib. <i>Annals of Oncology</i> , 2015, 26, vi37.	1.2	0
52	476 GJB5 association with BRAF mutation and survival in cutaneous melanoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, S296.	0.7	0
53	High-Throughput Identification of miRNA-Target Interactions in Melanoma Using miR-CATCHv2.0. <i>Methods in Molecular Biology</i> , 2021, 2265, 487-512.	0.9	0
54	CRISPR/Cas Technologies Applied to Pseudogenes. <i>Methods in Molecular Biology</i> , 2021, 2324, 265-284.	0.9	0

#	ARTICLE	IF	CITATIONS
55	The use of integrative genomics to define molecular signatures of melanoma histologic subtypes.. Journal of Clinical Oncology, 2010, 28, 8553-8553.	1.6	0
56	Preclinical analyses of a new gamma-secretase inhibitor targeting notch signaling in melanoma.. Journal of Clinical Oncology, 2010, 28, 8546-8546.	1.6	0
57	Abstract 425: Targeting embryonic signaling pathways in melanoma. , 2012, , .		0
58	Abstract LB-282: Two different strategies of delivery CRISPR/Cas9 system to gene edit rs4644 SNP inLGALS3gene. , 2017, , .		0